Your question is complex. Past human trials suggests 5 days is enough and that is backed up by some of the preclinical mouse data. On the other hand the COH group used Zantrene over 20 days, although I should add that they didn’t try to optomised this time. The real answer is it will vary with the drug combination used and the cancer type. We are exploring this question at the preclinical level and it will be looked at in the corresponding clinical trials.
Speculative M&A Transaction Analysis, page-587
- There are more pages in this discussion • 116 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.53 |
Change
0.115(8.16%) |
Mkt cap ! $248.7M | |||
| Open | High | Low | Value | Volume |
| $1.43 | $1.55 | $1.43 | $406.6K | 274.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3701 | $1.53 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.55 | 31089 | 2 |
View Market Depth
| Last trade - 15.59pm 13/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.52 |
Change
0.115 ( 9.79 %) |
||||
| Open | High | Low | Volume | ||
| $1.45 | $1.55 | $1.44 | 23501 | ||
| Last updated 15.58pm 13/05/2024 ? | |||||
| RAC (ASX) Chart |